APO Research
Talk to an analyst

APO RESEARCH · REPORT

Adalimumab Injection

Compare research editions
View pricing & licenses

Selected research

Market Structure

Global Adalimumab Injection Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032

22 December 2025199 pages

Choose your research edition.

Industry ResearchAdalimumab Injection Industry Research Report 2026133 pages · $2,950 USDIndustry Growth & TrendsGlobal Adalimumab Injection Industry Growth and Trends Forecast to 2032110 pages · $3,450 USDMarket StructureGlobal Adalimumab Injection Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032199 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Adalimumab Injection Market Outlook and Growth Opportunities 2026199 pages · $4,250 USDMarket Analysis & ForecastGlobal Adalimumab Injection Market Analysis and Forecast 2026-2032194 pages · $4,950 USD

Market perspective

The global Adalimumab Injection market is projected to grow from US$ million in 2026 to US$ million by 2032, implying a CAGR of % over 2026-2032.

The US & Canada market for Adalimumab Injection is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Adalimumab Injection is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Adalimumab Injection is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The China market for Adalimumab Injection is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Leading global manufacturers of Adalimumab Injection include Jiangsu Chia Tai-Tianqing Pharmaceutical, Innovent Biologics, Sandoz, Mylan, Hisun Biopharmaceutical, Shanghai Henlius Biotech, Fresenius Kabi, Bio-Thera Solutions, Ltd. and Amgen, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

This report provides an overview of the global Adalimumab Injection market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Adalimumab Injection and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Adalimumab Injection sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Adalimumab Injection market size, projected growth trends, production technologies, key applications, and end-use industries.

Adalimumab Injection Segment by Company

Jiangsu Chia Tai-Tianqing Pharmaceutical

Innovent Biologics

Sandoz

Mylan

Hisun Biopharmaceutical

Shanghai Henlius Biotech

Fresenius Kabi

Bio-Thera Solutions, Ltd.

Amgen

AbbVie

Zydus Group

Celltrion

Cadila Pharmaceuticals

Boehringer Ingelheim

Biogen

Adalimumab Injection Segment by Type

40mg/0.8ml

20mg/0.4ml

Adalimumab Injection Segment by Application

Hospitals

Clinics

Others

Adalimumab Injection Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global status and future forecast, involving, production, value, consumption, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, capacity, production, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Adalimumab Injection market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Adalimumab Injection and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Adalimumab Injection.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the Adalimumab Injection market, including product definition, global market growth prospects, market size, sales, and average price forecasts (2021-2032).

Chapter 2: Provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Detailed analysis of Adalimumab Injection manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales of Adalimumab Injection in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.

Chapter 7: Revenue of Adalimumab Injection in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights of the report

More report detail

Tables and figures
List of Tables Table 1. Adalimumab Injection Industry Trends Table 2. Adalimumab Injection Industry Drivers Table 3. Adalimumab Injection Industry Opportunities and Challenges Table 4. Adalimumab Injection Industry Restraints Table 5. Global Adalimumab Injection Revenue by Manufacturers (US$ Million) & (2021-2026) Table 6. Global Adalimumab Injection Revenue Market Share by Manufacturers (2021-2026) Table 7. Global Adalimumab Injection Sales by Manufacturers (k units) & (2021-2026) Table 8. Global Adalimumab Injection Sales Market Share by Manufacturers Table 9. Global Adalimumab Injection Average Sales Price (US$/unit) of Manufacturers (2021-2026) Table 10. Global Adalimumab Injection Industry Manufacturers Ranking, 2024 VS 2025 VS 2026 Table 11. Global Adalimumab Injection Key Manufacturers Manufacturing Sites & Headquarters Table 12. Global Adalimumab Injection Manufacturers, Product Type & Application Table 13. Global Adalimumab Injection Manufacturers Establishment Date Table 14. Global Manufacturers Market Concentration Ratio (CR5 and HHI) Table 15. Global Adalimumab Injection by Manufacturers Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue of 2025) Table 16. Major Manufacturers of 40mg/0.8ml Table 17. Major Manufacturers of 20mg/0.4ml Table 18. Global Adalimumab Injection Sales by Type 2021 VS 2025 VS 2032 (k units) Table 19. Global Adalimumab Injection Sales by Type (2021-2026) & (k units) Table 20. Global Adalimumab Injection Sales by Type (2027-2032) & (k units) Table 21. Global Adalimumab Injection Sales Market Share by Type (2021-2026) Table 22. Global Adalimumab Injection Sales Market Share by Type (2027-2032) Table 23. Global Adalimumab Injection Revenue by Type 2021 VS 2025 VS 2032 (k units) Table 24. Global Adalimumab Injection Revenue by Type (2021-2026) & (k units) Table 25. Global Adalimumab Injection Revenue by Type (2027-2032) & (k units) Table 26. Global Adalimumab Injection Revenue Market Share by Type (2021-2026) Table 27. Global Adalimumab Injection Revenue Market Share by Type (2027-2032) Table 28. Major Manufacturers of Hospitals Table 29. Major Manufacturers of Clinics Table 30. Major Manufacturers of Others Table 31. Global Adalimumab Injection Sales by Application 2021 VS 2025 VS 2032 (k units) Table 32. Global Adalimumab Injection Sales by Application (2021-2026) & (k units) Table 33. Global Adalimumab Injection Sales by Application (2027-2032) & (k units) Table 34. Global Adalimumab Injection Sales Market Share by Application (2021-2026) Table 35. Global Adalimumab Injection Sales Market Share by Application (2027-2032) Table 36. Global Adalimumab Injection Revenue by Application 2021 VS 2025 VS 2032 (k units) Table 37. Global Adalimumab Injection Revenue by Application (2021-2026) & (k units) Table 38. Global Adalimumab Injection Revenue by Application (2027-2032) & (k units) Table 39. Global Adalimumab Injection Revenue Market Share by Application (2021-2026) Table 40. Global Adalimumab Injection Revenue Market Share by Application (2027-2032) Table 41. Global Adalimumab Injection Sales by Region: 2021 VS 2025 VS 2032 (k units) Table 42. Global Adalimumab Injection Sales by Region (2021-2026) & (k units) Table 43. Global Adalimumab Injection Sales Market Share by Region (2021-2026) Table 44. Global Adalimumab Injection Sales Forecasted by Region (2027-2032) & (k units) Table 45. Global Adalimumab Injection Sales Forecasted Market Share by Region (2027-2032) Table 46. North America Adalimumab Injection Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (k units) Table 47. North America Adalimumab Injection Sales by Country (2021-2026) & (k units) Table 48. North America Adalimumab Injection Sales by Country (2027-2032) & (k units) Table 49. Europe Adalimumab Injection Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (k units) Table 50. Europe Adalimumab Injection Sales by Country (2021-2026) & (k units) Table 51. Europe Adalimumab Injection Sales by Country (2027-2032) & (k units) Table 52. Asia Pacific Adalimumab Injection Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (k units) Table 53. Asia Pacific Adalimumab Injection Sales by Country (2021-2026) & (k units) Table 54. Asia Pacific Adalimumab Injection Sales by Country (2027-2032) & (k units) Table 55. South America, Middle East and Africa Adalimumab Injection Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (k units) Table 56. South America, Middle East and Africa Adalimumab Injection Sales by Country (2021-2026) & (k units) Table 57. South America, Middle East and Africa Adalimumab Injection Sales by Country (2027-2032) & (k units) Table 58. Global Adalimumab Injection Revenue Grow Rate (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 59. Global Adalimumab Injection Revenue by Region (2021-2026) & (US$ Million) Table 60. Global Adalimumab Injection Revenue by Region (2027-2032) & (US$ Million) Table 61. Global Adalimumab Injection Revenue Market Share by Region (2021-2026) Table 62. Global Adalimumab Injection Revenue Market Share by Region (2027-2032) Table 63. Jiangsu Chia Tai-Tianqing Pharmaceutical Company Information Table 64. Jiangsu Chia Tai-Tianqing Pharmaceutical Business Overview Table 65. Jiangsu Chia Tai-Tianqing Pharmaceutical Adalimumab Injection Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 66. Jiangsu Chia Tai-Tianqing Pharmaceutical Adalimumab Injection Product Portfolio Table 67. Jiangsu Chia Tai-Tianqing Pharmaceutical Recent Development Table 68. Innovent Biologics Company Information Table 69. Innovent Biologics Business Overview Table 70. Innovent Biologics Adalimumab Injection Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 71. Innovent Biologics Adalimumab Injection Product Portfolio Table 72. Innovent Biologics Recent Development Table 73. Sandoz Company Information Table 74. Sandoz Business Overview Table 75. Sandoz Adalimumab Injection Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 76. Sandoz Adalimumab Injection Product Portfolio Table 77. Sandoz Recent Development Table 78. Mylan Company Information Table 79. Mylan Business Overview Table 80. Mylan Adalimumab Injection Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 81. Mylan Adalimumab Injection Product Portfolio Table 82. Mylan Recent Development Table 83. Hisun Biopharmaceutical Company Information Table 84. Hisun Biopharmaceutical Business Overview Table 85. Hisun Biopharmaceutical Adalimumab Injection Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 86. Hisun Biopharmaceutical Adalimumab Injection Product Portfolio Table 87. Hisun Biopharmaceutical Recent Development Table 88. Shanghai Henlius Biotech Company Information Table 89. Shanghai Henlius Biotech Business Overview Table 90. Shanghai Henlius Biotech Adalimumab Injection Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 91. Shanghai Henlius Biotech Adalimumab Injection Product Portfolio Table 92. Shanghai Henlius Biotech Recent Development Table 93. Fresenius Kabi Company Information Table 94. Fresenius Kabi Business Overview Table 95. Fresenius Kabi Adalimumab Injection Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 96. Fresenius Kabi Adalimumab Injection Product Portfolio Table 97. Fresenius Kabi Recent Development Table 98. Bio-Thera Solutions, Ltd. Company Information Table 99. Bio-Thera Solutions, Ltd. Business Overview Table 100. Bio-Thera Solutions, Ltd. Adalimumab Injection Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 101. Bio-Thera Solutions, Ltd. Adalimumab Injection Product Portfolio Table 102. Bio-Thera Solutions, Ltd. Recent Development Table 103. Amgen Company Information Table 104. Amgen Business Overview Table 105. Amgen Adalimumab Injection Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 106. Amgen Adalimumab Injection Product Portfolio Table 107. Amgen Recent Development Table 108. AbbVie Company Information Table 109. AbbVie Business Overview Table 110. AbbVie Adalimumab Injection Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 111. AbbVie Adalimumab Injection Product Portfolio Table 112. AbbVie Recent Development Table 113. Zydus Group Company Information Table 114. Zydus Group Business Overview Table 115. Zydus Group Adalimumab Injection Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 116. Zydus Group Adalimumab Injection Product Portfolio Table 117. Zydus Group Recent Development Table 118. Celltrion Company Information Table 119. Celltrion Business Overview Table 120. Celltrion Adalimumab Injection Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 121. Celltrion Adalimumab Injection Product Portfolio Table 122. Celltrion Recent Development Table 123. Cadila Pharmaceuticals Company Information Table 124. Cadila Pharmaceuticals Business Overview Table 125. Cadila Pharmaceuticals Adalimumab Injection Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 126. Cadila Pharmaceuticals Adalimumab Injection Product Portfolio Table 127. Cadila Pharmaceuticals Recent Development Table 128. Boehringer Ingelheim Company Information Table 129. Boehringer Ingelheim Business Overview Table 130. Boehringer Ingelheim Adalimumab Injection Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 131. Boehringer Ingelheim Adalimumab Injection Product Portfolio Table 132. Boehringer Ingelheim Recent Development Table 133. Biogen Company Information Table 134. Biogen Business Overview Table 135. Biogen Adalimumab Injection Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 136. Biogen Adalimumab Injection Product Portfolio Table 137. Biogen Recent Development Table 138. Key Raw Materials Table 139. Raw Materials Key Suppliers Table 140. Adalimumab Injection Distributors List Table 141. Adalimumab Injection Customers List Table 142. Research Programs/Design for This Report Table 143. Authors List of This Report Table 144. Secondary Sources Table 145. Primary Sources List of Figures Figure 1. Adalimumab Injection Product Image Figure 2. Global Adalimumab Injection Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Adalimumab Injection Market Size (2021-2032) & (US$ Million) Figure 4. Global Adalimumab Injection Sales (2021-2032) & (k units) Figure 5. Global Adalimumab Injection Average Price (US$/unit) & (2021-2032) Figure 6. Global Top 5 and 10 Adalimumab Injection Players Market Share by Revenue in 2025 Figure 7. Manufacturers Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 8. 40mg/0.8ml Image Figure 9. 20mg/0.4ml Image Figure 10. Global Adalimumab Injection Sales by Type (2021 VS 2025 VS 2032) & (k units) Figure 11. Global Adalimumab Injection Sales Market Share 2021 VS 2025 VS 2032 Figure 12. Global Adalimumab Injection Sales Market Share by Type (2021-2032) Figure 13. Global Adalimumab Injection Revenue by Type (2021 VS 2025 VS 2032) & (k units) Figure 14. Global Adalimumab Injection Revenue Market Share 2021 VS 2025 VS 2032 Figure 15. Global Adalimumab Injection Revenue Market Share by Type (2021-2032) Figure 16. Hospitals Image Figure 17. Clinics Image Figure 18. Others Image Figure 19. Global Adalimumab Injection Sales by Application (2021 VS 2025 VS 2032) & (k units) Figure 20. Global Adalimumab Injection Sales Market Share 2021 VS 2025 VS 2032 Figure 21. Global Adalimumab Injection Sales Market Share by Application (2021-2032) Figure 22. Global Adalimumab Injection Revenue by Application (2021 VS 2025 VS 2032) & (k units) Figure 23. Global Adalimumab Injection Revenue Market Share 2021 VS 2025 VS 2032 Figure 24. Global Adalimumab Injection Revenue Market Share by Application (2021-2032) Figure 25. North America Adalimumab Injection Sales and Growth Rate (2021-2032) & (k units) Figure 26. North America Adalimumab Injection Sales Market Share by Country (2021-2032) Figure 27. U.S. Adalimumab Injection Sales and Growth Rate (2021-2032) & (k units) Figure 28. Canada Adalimumab Injection Sales and Growth Rate (2021-2032) & (k units) Figure 29. Mexico Adalimumab Injection Sales and Growth Rate (2021-2032) & (k units) Figure 30. Europe Adalimumab Injection Sales and Growth Rate (2021-2032) & (k units) Figure 31. Europe Adalimumab Injection Sales Market Share by Country (2021-2032) Figure 32. Germany Adalimumab Injection Sales and Growth Rate (2021-2032) & (k units) Figure 33. France Adalimumab Injection Sales and Growth Rate (2021-2032) & (k units) Figure 34. U.K. Adalimumab Injection Sales and Growth Rate (2021-2032) & (k units) Figure 35. Italy Adalimumab Injection Sales and Growth Rate (2021-2032) & (k units) Figure 36. Netherlands Adalimumab Injection Sales and Growth Rate (2021-2032) & (k units) Figure 37. Asia Pacific Adalimumab Injection Sales and Growth Rate (2021-2032) & (k units) Figure 38. Asia Pacific Adalimumab Injection Sales Market Share by Country (2021-2032) Figure 39. China Adalimumab Injection Sales and Growth Rate (2021-2032) & (k units) Figure 40. Japan Adalimumab Injection Sales and Growth Rate (2021-2032) & (k units) Figure 41. South Korea Adalimumab Injection Sales and Growth Rate (2021-2032) & (k units) Figure 42. Southeast Asia Adalimumab Injection Sales and Growth Rate (2021-2032) & (k units) Figure 43. India Adalimumab Injection Sales and Growth Rate (2021-2032) & (k units) Figure 44. Australia Adalimumab Injection Sales and Growth Rate (2021-2032) & (k units) Figure 45. South America, Middle East and Africa Adalimumab Injection Sales and Growth Rate (2021-2032) & (k units) Figure 46. South America, Middle East and Africa Adalimumab Injection Sales Market Share by Country (2021-2032) Figure 47. Brazil Adalimumab Injection Sales and Growth Rate (2021-2032) & (k units) Figure 48. South Africa Adalimumab Injection Sales and Growth Rate (2021-2032) & (k units) Figure 49. Saudi Arabia Adalimumab Injection Sales and Growth Rate (2021-2032) & (k units) Figure 50. Turkey Adalimumab Injection Sales and Growth Rate (2021-2032) & (k units) Figure 51. Argentina Adalimumab Injection Sales and Growth Rate (2021-2032) & (k units) Figure 52. UAE Adalimumab Injection Sales and Growth Rate (2021-2032) & (k units) Figure 53. Egypt Adalimumab Injection Sales and Growth Rate (2021-2032) & (k units) Figure 54. Chile Adalimumab Injection Sales and Growth Rate (2021-2032) & (k units) Figure 55. Global Adalimumab Injection Revenue (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 56. Global Adalimumab Injection Revenue Market Share by Region in Percentage: 2025 Versus 2032 Figure 57. North America Adalimumab Injection Revenue (2021-2032) & (US$ Million) Figure 58. North America Adalimumab Injection Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 59. Europe Adalimumab Injection Revenue (2021-2032) & (US$ Million) Figure 60. Europe Adalimumab Injection Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 61. Asia-Pacific Adalimumab Injection Revenue (2021-2032) & (US$ Million) Figure 62. Asia-Pacific Adalimumab Injection Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 63. South America, Middle East and Africa Adalimumab Injection Revenue (2021-2032) & (US$ Million) Figure 64. South America, Middle East and Africa Adalimumab Injection Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 65. Adalimumab Injection Value Chain Figure 66. Manufacturing Cost Structure Figure 67. Adalimumab Injection Production Mode & Process Figure 68. Direct Comparison with Distribution Share Figure 69. Distributors Profiles Figure 70. Years Considered Figure 71. Research Process Figure 72. Key Executives Interviewed

Scope & coverage.

Types
  • 40mg/0.8ml
  • 20mg/0.4ml
Applications
  • Hospitals
  • Clinics
  • Others
Companies covered
  • Jiangsu Chia Tai-Tianqing Pharmaceutical
  • Innovent Biologics
  • Sandoz
  • Mylan
  • Hisun Biopharmaceutical
  • Shanghai Henlius Biotech
  • Fresenius Kabi
  • Bio-Thera Solutions, Ltd.
  • Amgen
  • AbbVie
  • Zydus Group
  • Celltrion
  • Cadila Pharmaceuticals
  • Boehringer Ingelheim
  • Biogen

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Adalimumab Injection Market Size, 2021 VS 2025 VS 2032
  3. 1.3 Global Adalimumab Injection Market Size Estimates and Forecasts (2021-2032)
  4. 1.4 Global Adalimumab Injection Sales Estimates and Forecasts (2021-2032)
  5. 1.5 Global Adalimumab Injection Market Average Price (2021-2032)
  6. 1.6 Assumptions and Limitations
  7. 1.7 Study Goals and Objectives
2 Global Adalimumab Injection Market Dynamics
  1. 2.1 Adalimumab Injection Industry Trends
  2. 2.2 Adalimumab Injection Industry Drivers
  3. 2.3 Adalimumab Injection Industry Opportunities and Challenges
  4. 2.4 Adalimumab Injection Industry Restraints
3 Adalimumab Injection Market by Manufacturers
  1. 3.1 Global Adalimumab Injection Revenue by Manufacturers (2021-2026)
  2. 3.2 Global Adalimumab Injection Sales by Manufacturers (2021-2026)
  3. 3.3 Global Adalimumab Injection Average Sales Price by Manufacturers (2021-2026)
  4. 3.4 Global Adalimumab Injection Industry Manufacturers Ranking, 2024 VS 2025 VS 2026
  5. 3.5 Global Adalimumab Injection Key Manufacturers Manufacturing Sites & Headquarters
  6. 3.6 Global Adalimumab Injection Manufacturers, Product Type & Application
  7. 3.7 Global Adalimumab Injection Manufacturers Establishment Date
  8. 3.8 Market Competitive Analysis
  9. 3.8.1 Global Adalimumab Injection Market CR5 and HHI
  10. 3.8.2 Global Top 5 and 10 Adalimumab Injection Players Market Share by Revenue in 2025
  11. 3.8.3 2025 Adalimumab Injection Tier 1, Tier 2, and Tier 3
4 Adalimumab Injection Market by Type
  1. 4.1 Adalimumab Injection Type Introduction
  2. 4.1.1 40mg/0.8ml
  3. 4.1.2 20mg/0.4ml
  4. 4.2 Global Adalimumab Injection Sales by Type
  5. 4.2.1 Global Adalimumab Injection Sales by Type (2021 VS 2025 VS 2032)
  6. 4.2.2 Global Adalimumab Injection Sales by Type (2021-2032)
  7. 4.2.3 Global Adalimumab Injection Sales Market Share by Type (2021-2032)
  8. 4.3 Global Adalimumab Injection Revenue by Type
  9. 4.3.1 Global Adalimumab Injection Revenue by Type (2021 VS 2025 VS 2032)
  10. 4.3.2 Global Adalimumab Injection Revenue by Type (2021-2032)
  11. 4.3.3 Global Adalimumab Injection Revenue Market Share by Type (2021-2032)
5 Adalimumab Injection Market by Application
  1. 5.1 Adalimumab Injection Application Introduction
  2. 5.1.1 Hospitals
  3. 5.1.2 Clinics
  4. 5.1.3 Others
  5. 5.2 Global Adalimumab Injection Sales by Application
  6. 5.2.1 Global Adalimumab Injection Sales by Application (2021 VS 2025 VS 2032)
  7. 5.2.2 Global Adalimumab Injection Sales by Application (2021-2032)
  8. 5.2.3 Global Adalimumab Injection Sales Market Share by Application (2021-2032)
  9. 5.3 Global Adalimumab Injection Revenue by Application
  10. 5.3.1 Global Adalimumab Injection Revenue by Application (2021 VS 2025 VS 2032)
  11. 5.3.2 Global Adalimumab Injection Revenue by Application (2021-2032)
  12. 5.3.3 Global Adalimumab Injection Revenue Market Share by Application (2021-2032)
6 Global Adalimumab Injection Sales by Region
  1. 6.1 Global Adalimumab Injection Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Adalimumab Injection Sales by Region (2021-2032)
  3. 6.2.1 Global Adalimumab Injection Sales by Region (2021-2026)
  4. 6.2.2 Global Adalimumab Injection Sales Forecasted by Region (2027-2032)
  5. 6.3 North America
  6. 6.3.1 North America Adalimumab Injection Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  7. 6.3.2 North America Adalimumab Injection Sales by Country (2021-2032)
  8. 6.3.3 U.S.
  9. 6.3.4 Canada
  10. 6.3.5 Mexico
  11. 6.4 Europe
  12. 6.4.1 Europe Adalimumab Injection Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  13. 6.4.2 Europe Adalimumab Injection Sales by Country (2021-2032)
  14. 6.4.3 Germany
  15. 6.4.4 France
  16. 6.4.5 U.K.
  17. 6.4.6 Italy
  18. 6.4.7 Netherlands
  19. 6.5 Asia Pacific
  20. 6.5.1 Asia Pacific Adalimumab Injection Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  21. 6.5.2 Asia Pacific Adalimumab Injection Sales by Country (2021-2032)
  22. 6.5.3 China
  23. 6.5.4 Japan
  24. 6.5.5 South Korea
  25. 6.5.6 Southeast Asia
  26. 6.5.7 India
  27. 6.5.8 Australia
  28. 6.6 South America, Middle East and Africa
  29. 6.6.1 South America, Middle East and Africa Adalimumab Injection Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  30. 6.6.2 South America, Middle East and Africa Adalimumab Injection Sales by Country (2021-2032)
  31. 6.6.3 Brazil
  32. 6.6.4 South Africa
  33. 6.6.5 Saudi Arabia
  34. 6.6.6 Turkey
  35. 6.6.6 Argentina
  36. 6.6.6 UAE
  37. 6.6.6 Egypt
  38. 6.6.6 Chile
7 Global Adalimumab Injection Revenue by Region
  1. 7.1 Global Adalimumab Injection Revenue by Region
  2. 7.1.1 Global Adalimumab Injection Revenue by Region: 2021 VS 2025 VS 2032
  3. 7.1.2 Global Adalimumab Injection Revenue by Region (2021-2026)
  4. 7.1.3 Global Adalimumab Injection Revenue by Region (2027-2032)
  5. 7.1.4 Global Adalimumab Injection Revenue Market Share by Region (2021-2032)
  6. 7.2 North America
  7. 7.2.1 North America Adalimumab Injection Revenue (2021-2032)
  8. 7.2.2 North America Adalimumab Injection Revenue Share by Country: 2021 VS 2025 VS 2032
  9. 7.3 Europe
  10. 7.3.1 Europe Adalimumab Injection Revenue (2021-2032)
  11. 7.3.2 Europe Adalimumab Injection Revenue Share by Country: 2021 VS 2025 VS 2032
  12. 7.4 Asia-Pacific
  13. 7.4.1 Asia-Pacific Adalimumab Injection Revenue (2021-2032)
  14. 7.4.2 Asia-Pacific Adalimumab Injection Revenue Share by Country: 2021 VS 2025 VS 2032
  15. 7.5 South America, Middle East and Africa
  16. 7.5.1 South America, Middle East and Africa Adalimumab Injection Revenue (2021-2032)
  17. 7.5.2 South America, Middle East and Africa Adalimumab Injection Revenue Share by Country: 2021 VS 2025 VS 2032
8 Company Profiles
  1. 8.1 Jiangsu Chia Tai-Tianqing Pharmaceutical
  2. 8.1.1 Jiangsu Chia Tai-Tianqing Pharmaceutical Company Information
  3. 8.1.2 Jiangsu Chia Tai-Tianqing Pharmaceutical Business Overview
  4. 8.1.3 Jiangsu Chia Tai-Tianqing Pharmaceutical Adalimumab Injection Sales, Price, Revenue and Gross Margin (2021-2026)
  5. 8.1.4 Jiangsu Chia Tai-Tianqing Pharmaceutical Adalimumab Injection Product Portfolio
  6. 8.1.5 Jiangsu Chia Tai-Tianqing Pharmaceutical Recent Developments
  7. 8.2 Innovent Biologics
  8. 8.2.1 Innovent Biologics Company Information
  9. 8.2.2 Innovent Biologics Business Overview
  10. 8.2.3 Innovent Biologics Adalimumab Injection Sales, Price, Revenue and Gross Margin (2021-2026)
  11. 8.2.4 Innovent Biologics Adalimumab Injection Product Portfolio
  12. 8.2.5 Innovent Biologics Recent Developments
  13. 8.3 Sandoz
  14. 8.3.1 Sandoz Company Information
  15. 8.3.2 Sandoz Business Overview
  16. 8.3.3 Sandoz Adalimumab Injection Sales, Price, Revenue and Gross Margin (2021-2026)
  17. 8.3.4 Sandoz Adalimumab Injection Product Portfolio
  18. 8.3.5 Sandoz Recent Developments
  19. 8.4 Mylan
  20. 8.4.1 Mylan Company Information
  21. 8.4.2 Mylan Business Overview
  22. 8.4.3 Mylan Adalimumab Injection Sales, Price, Revenue and Gross Margin (2021-2026)
  23. 8.4.4 Mylan Adalimumab Injection Product Portfolio
  24. 8.4.5 Mylan Recent Developments
  25. 8.5 Hisun Biopharmaceutical
  26. 8.5.1 Hisun Biopharmaceutical Company Information
  27. 8.5.2 Hisun Biopharmaceutical Business Overview
  28. 8.5.3 Hisun Biopharmaceutical Adalimumab Injection Sales, Price, Revenue and Gross Margin (2021-2026)
  29. 8.5.4 Hisun Biopharmaceutical Adalimumab Injection Product Portfolio
  30. 8.5.5 Hisun Biopharmaceutical Recent Developments
  31. 8.6 Shanghai Henlius Biotech
  32. 8.6.1 Shanghai Henlius Biotech Company Information
  33. 8.6.2 Shanghai Henlius Biotech Business Overview
  34. 8.6.3 Shanghai Henlius Biotech Adalimumab Injection Sales, Price, Revenue and Gross Margin (2021-2026)
  35. 8.6.4 Shanghai Henlius Biotech Adalimumab Injection Product Portfolio
  36. 8.6.5 Shanghai Henlius Biotech Recent Developments
  37. 8.7 Fresenius Kabi
  38. 8.7.1 Fresenius Kabi Company Information
  39. 8.7.2 Fresenius Kabi Business Overview
  40. 8.7.3 Fresenius Kabi Adalimumab Injection Sales, Price, Revenue and Gross Margin (2021-2026)
  41. 8.7.4 Fresenius Kabi Adalimumab Injection Product Portfolio
  42. 8.7.5 Fresenius Kabi Recent Developments
  43. 8.8 Bio-Thera Solutions, Ltd.
  44. 8.8.1 Bio-Thera Solutions, Ltd. Company Information
  45. 8.8.2 Bio-Thera Solutions, Ltd. Business Overview
  46. 8.8.3 Bio-Thera Solutions, Ltd. Adalimumab Injection Sales, Price, Revenue and Gross Margin (2021-2026)
  47. 8.8.4 Bio-Thera Solutions, Ltd. Adalimumab Injection Product Portfolio
  48. 8.8.5 Bio-Thera Solutions, Ltd. Recent Developments
  49. 8.9 Amgen
  50. 8.9.1 Amgen Company Information
  51. 8.9.2 Amgen Business Overview
  52. 8.9.3 Amgen Adalimumab Injection Sales, Price, Revenue and Gross Margin (2021-2026)
  53. 8.9.4 Amgen Adalimumab Injection Product Portfolio
  54. 8.9.5 Amgen Recent Developments
  55. 8.10 AbbVie
  56. 8.10.1 AbbVie Company Information
  57. 8.10.2 AbbVie Business Overview
  58. 8.10.3 AbbVie Adalimumab Injection Sales, Price, Revenue and Gross Margin (2021-2026)
  59. 8.10.4 AbbVie Adalimumab Injection Product Portfolio
  60. 8.10.5 AbbVie Recent Developments
  61. 8.11 Zydus Group
  62. 8.11.1 Zydus Group Company Information
  63. 8.11.2 Zydus Group Business Overview
  64. 8.11.3 Zydus Group Adalimumab Injection Sales, Price, Revenue and Gross Margin (2021-2026)
  65. 8.11.4 Zydus Group Adalimumab Injection Product Portfolio
  66. 8.11.5 Zydus Group Recent Developments
  67. 8.12 Celltrion
  68. 8.12.1 Celltrion Company Information
  69. 8.12.2 Celltrion Business Overview
  70. 8.12.3 Celltrion Adalimumab Injection Sales, Price, Revenue and Gross Margin (2021-2026)
  71. 8.12.4 Celltrion Adalimumab Injection Product Portfolio
  72. 8.12.5 Celltrion Recent Developments
  73. 8.13 Cadila Pharmaceuticals
  74. 8.13.1 Cadila Pharmaceuticals Company Information
  75. 8.13.2 Cadila Pharmaceuticals Business Overview
  76. 8.13.3 Cadila Pharmaceuticals Adalimumab Injection Sales, Price, Revenue and Gross Margin (2021-2026)
  77. 8.13.4 Cadila Pharmaceuticals Adalimumab Injection Product Portfolio
  78. 8.13.5 Cadila Pharmaceuticals Recent Developments
  79. 8.14 Boehringer Ingelheim
  80. 8.14.1 Boehringer Ingelheim Company Information
  81. 8.14.2 Boehringer Ingelheim Business Overview
  82. 8.14.3 Boehringer Ingelheim Adalimumab Injection Sales, Price, Revenue and Gross Margin (2021-2026)
  83. 8.14.4 Boehringer Ingelheim Adalimumab Injection Product Portfolio
  84. 8.14.5 Boehringer Ingelheim Recent Developments
  85. 8.15 Biogen
  86. 8.15.1 Biogen Company Information
  87. 8.15.2 Biogen Business Overview
  88. 8.15.3 Biogen Adalimumab Injection Sales, Price, Revenue and Gross Margin (2021-2026)
  89. 8.15.4 Biogen Adalimumab Injection Product Portfolio
  90. 8.15.5 Biogen Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 Adalimumab Injection Value Chain Analysis
  2. 9.1.1 Adalimumab Injection Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 Adalimumab Injection Production Mode & Process
  6. 9.2 Adalimumab Injection Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 Adalimumab Injection Distributors
  9. 9.2.3 Adalimumab Injection Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources
    8. 11.6 Disclaimer

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $3,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst